Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization
Eugene S Chung1, John Rickard2, Xiaoxiao Lu3
1The Christ Hospital Physicians, Ohio Heart and Vascular, Cincinnati, OH, USA.
Insights
Patients experiencing heart failure worsening after cardiac resynchronization therapy (CRT) incur substantial economic costs. Optimizing CRT may reduce this financial burden for heart failure (HF) patients.
Area of Science:
- Cardiology
- Health Economics
- Medical Device Therapy
Background:
- Cardiac resynchronization therapy (CRT) is used for heart failure (HF) patients, but a significant portion do not respond.
- Non-response to CRT can lead to worsening HF, impacting patient outcomes and healthcare resource utilization.
Purpose of the Study:
- To assess the economic burden associated with heart failure (HF) worsening in patients who received cardiac resynchronization therapy (CRT).
- To compare healthcare resource utilization and costs between patients with and without HF worsening post-CRT.
Main Methods:
- Retrospective claims-based study using de-identified US insurance data (2007-2018).
- 12,753 adult patients receiving CRT were stratified into cohorts based on HF worsening within 180 days post-implantation.
- Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics; annualized HRU and costs were compared.
Main Results:
- Patients with HF worsening (n=4785) showed significantly higher annual inpatient, outpatient, and emergency department visits compared to those without (n=7968).
- Mean annual total payer-paid amounts were 68% higher, and patient-paid medical costs were 31% higher for patients with HF worsening.
- Congestive heart failure-related healthcare resource utilization and costs also remained significantly higher in the worsening HF cohort.
Conclusions:
- Worsening heart failure following cardiac resynchronization therapy results in a substantial incremental economic burden.
- Strategies focused on optimizing CRT effectiveness may help mitigate these increased healthcare costs and resource utilization.
Introduction:
Although cardiac resynchronization therapy (CRT) has the potential to improve cardiac function in patients with heart failure (HF), a considerable portion of patients do not respond to therapy. This study assessed the economic burden among patients with and without HF worsening after receiving CRT in real-world practice.
Methods:
In this retrospective claims-based study using Optum's de-identified Clinformatics® Data Mart Database (January 2007-December 2018), adults who received CRT were stratified into two cohorts based on whether they showed evidence of HF worsening within 180 days post-CRT implantation. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding, accounting for demographics (e.g., age, sex), the Quan-Charlson Comorbidity Index, other clinical characteristics, healthcare resource utilization (HRU), and healthcare costs during the 180 days pre-CRT (baseline period). Annualized all-cause and congestive HF-related HRU and healthcare costs from payer and patient perspectives were assessed from day 181 post-CRT (follow-up period), and compared between cohorts using incidence rate ratios (IRRs) and cost ratios (CRs).
Results:
This study included 12,753 patients (n = 4785 with HF worsening; n = 7968 without). Mean age was 72 years and roughly two-thirds were male. Baseline characteristics were balanced between cohorts post-IPTW. During follow-up, patients with HF worsening had significantly greater annual all-cause inpatient [adjusted IRR (95% confidence interval) = 1.55 (1.44, 1.66), p < 0.001], outpatient [adjusted IRR = 1.46 (1.32, 1.61), p < 0.001], and emergency department [adjusted IRR = 1.31 (1.22, 1.41), p < 0.001] visits. Mean annual total per patient payer-paid amounts were significantly higher for patients with HF worsening versus without HF worsening [adjusted CR = 1.68 (1.56, 1.80), p < 0.001]. Annual patient-paid medical costs were also higher for patients with HF worsening [adjusted CR = 1.31 (1.25, 1.38), p < 0.001]. Results were similar for congestive HF-related HRU and costs.
Conclusions:
The incremental economic burden among patients with HF worsening following CRT is substantial. Efforts aimed at CRT optimization may help reduce this burden.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:22Heart Failure VI: Adjunct Therapies
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Heart Failure V: Medical Management